Real Life of Aflibercept In FraNce: oBservatiOnnal study in Wet AMD (RAINBOW)
The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated
- Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made - Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled - Prior/current treatment with any anti-VEGF intravitreal injections or macular laser (laser and/or visudyne/PDT) in the fellow eye is allowed - Man or woman aged 18 years or more - Patient who has been given appropriate information about the study objectives and procedures and who has given his/her written, informed consent;
- Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks - Patient who does not meet the local indication criteria for Eylea treatment.Contraindications listed in the Summary of Product Characteristics (SmPC) must be taken into account - Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or any anti-VEGF intravitreal injections for the study eye - Patient taking part in an interventional study at the time of enrolment.
Many Locations, France
E-mail: [email protected]
Phone: (+)1-888-84 22937
A retrospective and prospective non-interventional open label study to assess the real life of treatment-naive patients with wet age-related macular degeneration in routine clinical practice in France and starting an Anti VEGF Therapy with Aflibercept